Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations

Expert Opinion on Drug Safety · Published 2026-05-11 · DOI 10.1080/14740338.2026.2672427

Authors being retrieved — see the publisher record. https://doi.org/10.1080/14740338.2026.2672427

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Comparison of ciprofol and propofol on dreaming and emotional response during painless gastroscopy: a single-center randomized controlled trial · Expert Opinion on Drug Safety · 2025 · Same journal
Rare irAEs associated with immune checkpoint inhibitor therapy · Expert Opinion on Drug Safety · 2026 · Same journal
Safety and optimal use of direct oral anticoagulant therapy · Expert Opinion on Drug Safety · 2025 · Same journal
Safe prescribing of antihypertensive drugs in the elderly and managing the risk of adverse events · Expert Opinion on Drug Safety · 2026 · Same journal
Long-term efficacy and safety of intra-articular corticosteroid injections in patients with knee osteoarthritis · Expert Opinion on Drug Safety · 2026 · Same journal
Lessons from examining the safety of drugs for COVID-19 during pregnancy · Expert Opinion on Drug Safety · 2026 · Same journal
COVID-19 vaccine safety studies- the need for a third group for extended monitoring · Expert Opinion on Drug Safety · 2025 · Same journal
Safety and efficacy of hormonal therapies used to treat endometriosis in women suffering migraine · Expert Opinion on Drug Safety · 2026 · Same journal
Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS database · Expert Opinion on Drug Safety · 2026 · Same journal
Trigger tool methodologies in hospital settings: reappraising their role in pharmacovigilance and digital safety surveillance · Expert Opinion on Drug Safety · 2026 · Same journal